Global Renal Cell Cancer (RCC) Disease Forecast and Market Analysis to 2035 - ResearchAndMarkets.com

September 5, 2018

DUBLIN--(BUSINESS WIRE)--Sep 5, 2018--The “Renal Cell Cancer (RCC) Disease Forecast and Market Analysis to 2035” report has been added to ResearchAndMarkets.com’s offering.

Renal cell cancer (RCC) is a tumor that originates in the renal cortex, the outer part of the kidney between the renal capsule and the renal medulla. Around 85% of all malignant kidney tumors are RCC, with other types including transitional cell carcinoma of the renal pelvis and Wilms’ tumor (nephroblastoma). The incidence of RCC is higher in those over the age of 60 years, suggesting that the aging population may play a significant role in current and future disease burden. Overall, RCC incidence rates have been steadily increasing in both men and women in the US, Japan, and five major EU markets since the 1970s.

Market snapshot

The RCC market will experience moderate growth despite a number of patent expiries of key brands over the forecast period. Sutent continues to be the most widely prescribed therapy in locally advanced and metastatic renal cell cancer. Incident cases of renal cell carcinoma are expected to increase by more than a quarter during 2016-36. Sutent is currently the standard of care for newly diagnosed RCC patients, with Afinitor the standard of care in the second-line setting. Companies are increasingly developing pipeline drugs to use in combination with currently marketed therapies.

Key Topics Covered:

1 Forecast: Renal Cell Cancer

Executive Summary Market Overview And Trends Methodology And Market Definition Afinitor (Everolimus) Avastin (Bevacizumab) Avelumab Cabometyx (Cabozantinib) Inlyta (Axitinib) Keytruda (Pembrolizumab) Lenvima (Lenvatinib) Nexavar (Sorafenib) Opdivo (Nivolumab) Sutent (Sunitinib) Tecentriq (Atezolizumab) Torisel (Temsirolimus) Votrient (Pazopanib) Primary Research Methodology

2 Treatment: Renal Cell Cancer

Executive Summary Primary Research Methodology Disease Definition And Diagnosis Patient Segmentation Current Treatment Options Prescribing Trends

3 Epidemiology: Renal Cell Carcinoma

Executive Summary Disease Background Methodology Forecast Bibliography Appendix: Additional Sources

4 Marketed Drugs: Renal Cell Cancer

Executive Summary Product Overview Appendix

5 Product Profile

Afinitor Avastin Cabometyx Inlyta Lenvima Nexavar Opdivo Sutent Torisel Votrient

6 Pipeline: Renal Cell Cancer

Executive Summary Clinical Pipeline Overview Recently Discontinued Drugs Comparator Therapy Clinical Trial Design Appendix

7 Product Profile (Late Stage):

Keytruda Tecentriq Avelumab

For more information about this report visit https://www.researchandmarkets.com/research/j6vzsq/global_renal_cell?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180905005463/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Kidney Cancer Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/05/2018 06:59 AM/DISC: 09/05/2018 06:59 AM


Update hourly